Medidata Solutions Inc (NASDAQ:MDSO) – Research analysts at KeyCorp cut their FY2018 EPS estimates for Medidata Solutions in a note issued to investors on Sunday, November 18th. KeyCorp analyst D. Hooker now anticipates that the company will earn $0.82 per share for the year, down from their prior forecast of $0.83.

Medidata Solutions (NASDAQ:MDSO) last released its quarterly earnings data on Thursday, October 18th. The company reported $0.42 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.36 by $0.06. Medidata Solutions had a return on equity of 10.70% and a net margin of 8.43%. The company had revenue of $163.41 million during the quarter, compared to analysts’ expectations of $162.09 million. During the same period last year, the firm posted $0.33 earnings per share. The business’s revenue was up 17.6% on a year-over-year basis.

A number of other analysts have also recently issued reports on MDSO. Needham & Company LLC cut Medidata Solutions from a “buy” rating to a “hold” rating in a research report on Wednesday, July 25th. ValuEngine raised Medidata Solutions from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. BidaskClub raised Medidata Solutions from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 16th. Royal Bank of Canada set a $86.00 price objective on Medidata Solutions and gave the company a “buy” rating in a research report on Friday, October 19th. Finally, Zacks Investment Research cut Medidata Solutions from a “hold” rating to a “sell” rating in a research report on Tuesday, October 16th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $84.64.

MDSO opened at $72.91 on Wednesday. Medidata Solutions has a 12-month low of $59.60 and a 12-month high of $88.87. The company has a market capitalization of $4.20 billion, a PE ratio of 85.78, a price-to-earnings-growth ratio of 4.06 and a beta of 1.30. The company has a quick ratio of 2.52, a current ratio of 2.52 and a debt-to-equity ratio of 0.15.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Oregon Public Employees Retirement Fund increased its stake in shares of Medidata Solutions by 3.0% during the second quarter. Oregon Public Employees Retirement Fund now owns 22,786 shares of the company’s stock worth $1,836,000 after purchasing an additional 666 shares during the period. Front Row Advisors LLC increased its stake in shares of Medidata Solutions by 6.1% during the second quarter. Front Row Advisors LLC now owns 12,623 shares of the company’s stock worth $980,000 after purchasing an additional 725 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Medidata Solutions by 5.8% during the third quarter. Thrivent Financial for Lutherans now owns 14,280 shares of the company’s stock worth $1,047,000 after purchasing an additional 787 shares during the period. Polen Capital Management LLC increased its stake in shares of Medidata Solutions by 12.2% during the second quarter. Polen Capital Management LLC now owns 7,413 shares of the company’s stock worth $597,000 after purchasing an additional 806 shares during the period. Finally, Bahl & Gaynor Inc. increased its stake in shares of Medidata Solutions by 2.0% during the third quarter. Bahl & Gaynor Inc. now owns 41,537 shares of the company’s stock worth $3,045,000 after purchasing an additional 825 shares during the period.

In other news, EVP Michael I. Otner sold 7,030 shares of the stock in a transaction that occurred on Tuesday, October 23rd. The stock was sold at an average price of $69.40, for a total transaction of $487,882.00. Following the transaction, the executive vice president now owns 62,548 shares in the company, valued at $4,340,831.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.70% of the stock is currently owned by company insiders.

Medidata Solutions Company Profile

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.

Featured Story: How Does the Quiet Period Work?

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.